Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leniolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 5/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leniolisib SCHEMBL323054 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL29370516 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL30089313 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789521 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789551 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789594 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789520 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789519 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL30767853 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL29369662 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | claimed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | claimed |
| CN-108601786-B | Use of inhibitors of the activity or function of PI3K for the treatment of primary sjogren's syndrome | 诺华股份有限公司 | 2021-11-02 | — | — | CN | claimed |
| EP-3695840-A1 | USE OF LENIOLISIB IN THE TREATMENT OF PRIMARY SJÖGREN'S SYNDROME | Novartis AG (CH) | 2020-08-19 | — | — | EP | claimed |
| EP-3413894-B1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJÖGREN'S SYNDROME | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | claimed |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | claimed |
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2019-02-07 | — | — | US | claimed |
| US-20190038628-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJOGREN'S SYNDROME | NOVARTIS PHARMA AG (CH) | 2019-02-07 | — | — | US | claimed |
| EP-3413894-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJÖGREN'S SYNDROME | Novartis AG (CH) | 2018-12-19 | — | — | EP | claimed |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2018-09-20 | — | — | US | claimed |
| EP-2790705-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | Novartis AG (CH) | 2014-10-22 | — | — | EP | claimed |
| EP-2590974-B1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-21 | — | — | EP | claimed |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| EP-2723740-A1 | SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2014-04-30 | — | — | EP | claimed |
| US-8653092-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2014-02-18 | — | — | US | claimed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | claimed |
| EP-2590974-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-05-15 | — | — | EP | claimed |
| WO-2013001445-A1 | SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-03 | — | — | WO | claimed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | claimed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20190038628-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJOGREN'S SYNDROME | PIK3CA, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 6/4885 |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 3/4885 |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.